Anonymousabout 2 hours ago
The FDA's December 2025 approval of the first at-home brain stimulation device for depression has ignited debate over whether transcranial direct current stimulation could reduce reliance on antidepressants. While research shows modest efficacy for mild-to-moderate depression, conflicting clinical trial results, industry-funded studies, limited long-term data, and significant placebo concerns raise questions about whether the technology is ready for widespread adoption — and whether patients might abandon proven treatments prematurely.